PD-0325901 MEK選擇性非競爭型抑制劑| 貨號1643-25 A MEK inhibitor
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
PD-0325901 | MEK選擇性非競爭型抑制劑| 貨號1643-25 A MEK inhibitor
Alternate Name/Synonyms: N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2[(2-fluoro-4-iodophenyl)amino]-benzamide
PD-0325901一種選擇性及ATP非競爭性之MEK抑制劑；抑制鼠結腸26腫瘤中ERK的磷酸化（IC 50 = 0.33nM）； 與GSK-3抑制劑CHIR99021結合，防止細胞分化cell differentiation和維持胚胎幹（ES）細胞的自我更新self-renewal。分子型式C₁₆H₁₄F₃IN₂O₄ | 分子量Molecular Weight: 482.2 | 純度Purity: ≥95% by HPLC | Solubility: DMSO (20 mg/ml) of EtOH (20 mg/ml)
| Catalog # | Product Name+ | Size |
| 1594-100 | BAY 43-9006 | 100 mg |
| 1594-25 | BAY 43-9006 | 25 mg |
| 1954-5 | Doramapimod | 5 mg |
| 1954-25 | Doramapimod | 25 mg |
| 1783-5 | EZSolution™ PD 98059 | 5 mg |
| 1871-1 | EZSolution™ PD184352 | 1 mg |
| 1786-1 | EZSolution™ SB 203580 | 1 mg |
| 2729-5 | JNK-IN-8 | 5 mg |
| 2729-25 | JNK-IN-8 | 25 mg |
| 7011-50 | L-JNK Peptide Inhibitor I | 50 µl |
| K862-7 | PathwayReady™ MAP Kinase Signaling Inhibitor Panel | 7 inhibitors |
| 1666-5 | PD 98059 | 5 mg |
| 1643-2 | PD-0325901 | 2 mg |
| 1643-5 | PD-0325901 | 5 mg |
| 1643-25 | PD-0325901 | 25 mg |
| 1585-25 | PD184352 | 25 mg |
| 1585-5 | PD184352 | 5 mg |
| 1585-1 | PD184352 | 1 mg |
| 1712-1 | SB 203580 | 1 mg |
| 1712-5 | SB 203580 | 5 mg |
| 1669-5 | SP600125 | 5 mg |
| 1668-5 | U0126 | 5 mg |
| 1598-1 | VX-702 | 1 mg |
| 1598-5 | VX-702 | 5 mg |
